Swiss startups strengthen presence in North America

The establishment of its U.S. office in Cambridge (MA) marks a significant step in Attolight’s mission to enhance service and support for its customers in North American by offering localized expertise and tailored assistance. The company is a leader in Cathodoluminescence and advanced spectroscopic solutions for defect inspection and high-end material research.

“Our new U.S. office brings us closer to our customers, enabling us to better understand their needs and foster stronger collaboration,” said our CEO Samuel Sonderegger, who relocated to Cambridge. “This expansion reinforces our commitment to the region and our drive to continue innovating with state-of-the-art spectroscopy solutions.”

Blocksport sets base in New York City
Blocksport has opened a new office in New York City, reinforcing its ongoing efforts to expand its presence in key markets worldwide while fostering closer relationships with sports organizations, clubs, and leagues in North America. The company is already recognized for its innovative fan engagement platforms and tailored solutions for the sports industry, which include gamification, digital collectibles, and community-building tools. Associations such as Partizan BC, Boavista FC, Telekom Baskets Bonn, Monaco Basket, and many more clubs, leagues, and federations use Blocksport to build stronger connections with their fans while exploring new revenue opportunities. The New York City office will serve as Blocksport's hub for its U.S. operations, with David Ricca leading the charge as the company's Director of Growth in the United States.

Newbiologix opens subsidiary in the USA
NewBiologix, which is pioneering efficient, cost-effective, and scalable production of viral vectors for gene and cell therapy announced the establishment of its U.S. subsidiary serving as the company’s US hub that offers real-time support and collaboration for gene and cell therapy companies in the world’s largest biotech market. NewBiologix recently launched the Xcell™ Portfolio, a suite of advanced technologies that provides deep insights and comprehensive analysis of rAAV quality—an ongoing challenge in the field. By integrating its proprietary HEK293-based cell lines with advanced production tools and analytical testing services, the Xcell Portfolio streamlines the journey from research to commercialization, accelerating the development of safer and more effective gene therapies for patients.
In line with the expansion, the company has appointed David Kelly as Business Development Manager to lead the U.S. operation and head business development. Kelly brings a unique blend of technical expertise and commercial acumen to NewBiologix. He has more than a decade of experience in gene and cell therapy, as well as stem cell manufacturing and commercial development. He will oversee sales and support for NewBiologix services and licensing opportunities for clients across the U.S. and Canada.

(RAN)